Renal Denervation

The story of renal denervation and its spectacular and shocking failure in 2014 is one of the more dramatic narratives in the medical device industry, and one that we at DRG Medtech have been following closely for more than 6 years. Through his ongoing blog series outlined below, Sean Messenger,...

I promise I care about non-renal denervation medical devices. Really, I do. But this area is just so dynamic that it keeps drawing my attention. So be it. I was there, sitting in the main presentation hall at the Walter E Washington Convention Center, when the

Renal denervation was the single hottest topic in cardiovascular medtech for two years, the star prospect of an industry hungry for growth stories. That, however, was before negative results of the pivotal SYMPLICITY HTN-3 trial were announced in January 2014 ...

This morning, an announcement from Medtronic rocked one of the hottest markets in medtech: renal denervation, the device-based treatment for hypertension. Medtronic announced that the results from its SYMPLICITY HTN-3 trial failed to meet its primary efficacy ...

As we mentioned in an earlier post, renal denervation was set to be one of the biggest trends in medtech in 2012, and it hasn?t failed us. It's been a hot topic at numerous conferences this year, including the

I think we can all agree that as we come out of a rough 2011 for medtech, a number of questions are weighing on everyone's minds for 2012. How will fears of a second recession and growing problems in the troubled European economies affect medtech? What new emerging technologies have great potential...